Asparaginase

From Wikipedia, the free encyclopedia

Image:Asparaginase.png
Asparaginase
Systematic (IUPAC) name
E. coli L-asparagine amidohydrolase
Identifiers
CAS number 9015-68-3
ATC code L01XX02
PubChem  ?
DrugBank BTD00011
Chemical data
Formula C1377H2208N382O442S17 
Mol. mass 31731.9 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life 8-30 hrs
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Asparaginase (EC 3.5.1.1) is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid. It is also marketed under the brand name Elspar® to treat acute lymphoblastic leukemia (ALL). It can be given intramuscularly or intravenously.

[edit] Mechanism of action

The rationale behind asparaginase is that it takes advantage of the fact that ALL cells are unable to synthesize the non-essential amino acid asparagine whereas normal cells are able to make their own asparagine. These leukemic cells depend on circulating asparagine. Asparaginase however catalyzes the conversion of L-asparagine to aspartic acid and ammonia. This deprives the leukemic cell of circulating asparagine.

[edit] Side effects

The main side effect is an allergic or hypersensitivity reaction. Asparaginase has also been associated with pancreatitis. Additionally, it can also be associated with a coagulopathy as it decreases protein synthesis, including synthesis of coagulation factors and anticoagulant factor, leading to bleeding or thrombotic events.



In other languages